• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[The effect of prolonged acenocoumarol therapy on bone density].

作者信息

Kiss J, Tihanyi L, Nagy E, Végh Z, Deli A, Tahy A, Korányi L

机构信息

Dunántúli Osteoporosis Decentrum, Allami Szívkórház, Balatonfüred.

出版信息

Orv Hetil. 1995 Sep 24;136(39):2113-5.

PMID:7566945
Abstract

The effect of chronic cumarin treatment on bone mineral content was investigated. Bone mineral density was determined by double photon densitometry (Lunar DPXL). The density data (mean +/- SE) of 45 cardiac patients (age: 57.0 = +/- 6.3 y, body mass index: 26.7 +/- 3.8 kp/m2, cardiac stadium score, according to New York Heart Association: 2-3), had been treated by acenocumarol at least for 2 years (duration of treatment: 75.0 +/- 52 months), were compared to the values of 45 age, body mass index, cardiac status matched patients not treated by anticoagulant. The density values of L2-L4 lumbar regions were lower in the treated group (1.041 +/- 0.17 vs. controlls: 1.13 +/- 0.15 g/cm2, p < 0.05), while no differences in ultradistal ulnar and radial regions were detected. No correlation between bone mineral density and the length, or the dose of the cumarin treatment were observed. This observation suggests the importance of the regular bone densitometry control of cumarin treated patient.

摘要

相似文献

1
[The effect of prolonged acenocoumarol therapy on bone density].
Orv Hetil. 1995 Sep 24;136(39):2113-5.
2
[Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].[儿童急性淋巴细胞白血病治疗患者的骨质增生]
Pol Merkur Lekarski. 2007 Oct;23(136):271-5.
3
Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy.类风湿关节炎患者骨密度的评估。疾病活动度和糖皮质激素治疗的影响。
Rev Rhum Engl Ed. 1997 Jul-Sep;64(7-9):451-8.
4
Heritability of bone mineral density.骨密度的遗传力。
Rev Rhum Engl Ed. 1999 Mar;66(3):146-51.
5
[Effects of body mass index on bone mineral density in men].[体重指数对男性骨密度的影响]
Orv Hetil. 2005 Jul 10;146(28):1489-93.
6
[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].[细胞色素P450 2C9基因型对接受醋硝香豆素治疗患者出血并发症的意义]
Orv Hetil. 2005 Apr 17;146(16):739-43.
7
[Bone density and mineral content in normal men. Measurement by dual photon densitometry].
Rev Med Chil. 1993 Sep;121(9):1006-11.
8
Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.儿童急性淋巴细胞白血病幸存者骨矿物质密度和身体成分的改善:一项为期1年的前瞻性研究。
Pediatrics. 2005 Jul;116(1):e102-8. doi: 10.1542/peds.2004-1838.
9
Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.活动性类风湿关节炎患者在抗TNF-α治疗期间的骨代谢变化。
Ann N Y Acad Sci. 2006 Jun;1069:420-7. doi: 10.1196/annals.1351.040.
10
[Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].[激素替代疗法对绝经后女性无抗骨质疏松作用]
Ginecol Obstet Mex. 2004 Jul;72:349-55.